225 related articles for article (PubMed ID: 15895440)
1. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
Heinrich MC; Corless CL
J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors and the evolution of targeted therapy.
Sanborn RE; Blanke CD
Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumors (GISTs): a pathology view point.
Sornmayura P
J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal stromal tumor.
Gupta P; Tewari M; Shukla HS
Surg Oncol; 2008 Aug; 17(2):129-38. PubMed ID: 18234489
[TBL] [Abstract][Full Text] [Related]
6. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
Shiba K; Matsumoto T; Hirota S
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
[TBL] [Abstract][Full Text] [Related]
7. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
8. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic targets in gastrointestinal stromal tumors].
Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
[TBL] [Abstract][Full Text] [Related]
10. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
11. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal stromal tumor: 5 years later.
van der Zwan SM; DeMatteo RP
Cancer; 2005 Nov; 104(9):1781-8. PubMed ID: 16136600
[TBL] [Abstract][Full Text] [Related]
13. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
15. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses.
Kikuchi H; Yamashita K; Kawabata T; Yamamoto M; Hiramatsu Y; Kondo K; Baba M; Ohta M; Kamiya K; Tanaka T; Suzuki S; Kitagawa K; Kitagawa M; Sugimura H; Konno H
Cancer Sci; 2006 Feb; 97(2):127-32. PubMed ID: 16441423
[TBL] [Abstract][Full Text] [Related]
17. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
[TBL] [Abstract][Full Text] [Related]
19. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
20. [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
Siewert E; Tietze L; Maintz C; Geier A; Dietrich CG; Matern S; Gartung C
Z Gastroenterol; 2004 Mar; 42(3):233-42. PubMed ID: 15022111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
